
About Retrophin
Retrophin is a publicly listed company based in San Diego (United States) founded in 2011. Drugs are developed for debilitating and life-threatening diseases. Retrophin has raised $29 million across 2 funding rounds from investors including MSMBAinUSA. The company has 380 employees. Retrophin has completed 2 acquisitions, including Manchester Pharma and Orphan Technologies. Its chief executive, as recorded, is Eric Dube. Its focus areas include Diversified Pharmaceuticals. Its legal entity is RETROPHIN, INC.
Company details
Founded in 2011 and based in San Diego, United States, Retrophin operates in the biopharmaceutical sector. Focus is placed on the discovery, acquisition, development, and commercialization of therapies targeting diseases with limited treatment options. Three drugs are currently marketed for homozygous cystinuria, bile acid synthesis disorders, and gallstones. Additional candidates are in development for focal segmental glomerulosclerosis and pantothenate kinase-associated neurodegeneration. Leadership is provided by CEO Eric Dube.
- Headquarters San Diego, United States
- Employees 380
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website retrophin.com
- Social LinkedIn X Facebook
- Legal Name Retrophin, Inc.
- Total Equity Funding$29M (USD)
in 2 rounds
- Latest Funding Round$25M (USD), Series B
Oct 2013
- Investors
- Employee Count380
- Investments & AcquisitionsManchester Pharma
& 1 more
Funding Insights of Retrophin
Retrophin has successfully raised a total of $29M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29M
- Total Rounds 2
- Last Round Series B β $25M
- First Round $4M
(May 2012)
- Investors Count 1
All 2 funding rounds of Retrophin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2013 | $25M | Series B | β | β | β |
| May 2012 | $4M | Series A | β | β |
1 investors in total: 1 institutional.
Investors in Retrophin
Retrophin has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include MSMBAinUSA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides online guidance for students seeking to study abroad. | 2013 | msmbainusa.com | Mumbai, India |
Investor details for Retrophin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Retrophin
5 people are tracked at Retrophin (4 in leadership, 1 in team); the tracked headcount is 380.
| Name | Role | Group |
|---|---|---|
Eric Dube | CEO | Leadership |
Noah L. Rosenberg | Chief Medical Officer | Leadership |
Laura M. Clague | Chief Financial Officer | Leadership |
Peter Heerma | Chief Commercial Officer | Leadership |
Elizabeth Reed | General Counsel and Corporate Secretary | Team |
Complete people profiles for Retrophin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Retrophin
Retrophin has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Manchester Pharma and Orphan Technologies.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Enzyme replacement therapy for homocystinuria is being developed. | orphantechnologies.com | Lexington, United States | 2010 | Oct 2020 | $90M | |
Therapeutic modalities for ultra-rare diseases are developed and commercialized. | manchesterpharma.com | Fort Collins, United States | 2008 | Feb 2014 | $62.5M |
Complete acquisition details for Retrophin
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Retrophin
6 dated milestones of Retrophin across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Retrophin is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series B, of $25.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Manchester Pharma.
- Acquisition Acquires Orphan Technologies.
Web traffic of Retrophin
Websites that share an audience with Retrophin (retrophin.com).
Websites whose visitors overlap most with Retrophin. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| missionpharmacal.com | 100% | 2.8K | #8,693,471 | View details | |
| arraybiopharma.com | 98% | View details | |||
dddmag.com | dddmag.com | 85% | β | ||
ppdi.com | ppdi.com | 85% | #404,899 | β | |
| takeda.com | 85% | 620.1K | #93,966 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 14 similar websites and full traffic analytics for Retrophin
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Retrophin (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Retrophin
Complete news archive for Retrophin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Retrophin
Retrophin was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Retrophin is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Eric Dube is the CEO of Retrophin, as recorded in our data.
Retrophin is a funded company, having raised a total of $29M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on May 2012.
Retrophin has 380 employees.
Founded in 2011 and based in San Diego, United States, Retrophin operates in the biopharmaceutical sector. Focus is placed on the discovery, acquisition, development, and commercialization of therapies targeting diseases with limited treatment options. Three drugs are currently marketed for homozygous cystinuria, bile acid synthesis disorders, and gallstones. Additional candidates are in development for focal segmental glomerulosclerosis and pantothenate kinase-associated neurodegeneration. Leadership is provided by CEO Eric Dube.
Retrophin has made 2 acquisitions, including Manchester Pharma, and Orphan Technologies.
Retrophin has 1 investor. Key investors include MSMBAinUSA.
Retrophin operates through Retrophin, Inc..
